(Solid Tumors, Lung Cancer) What Is the Recommended Dose of Rozlytrek (Entrectinib)?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
FDA Approves Rozlytrek for NTRK Fusion-Positive Tumors and ROS1-Positive NSCLC
- September 21, 2019
- Reading time: 2 minutes
On August 16, 2019, the US Food and Drug Administration (FDA) approved Rozlytrek (entrectinib) for:
- Adult and pediatric patients with solid tumors harboring NTRK gene fusions that are metastatic, where surgical resection would likely result in severe morbidity, or that have progressed following treatment, or when no satisfactory alternative treatment exists
- Patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC)
NTRK-Positive Solid Tumors
Efficacy was validated in three multicenter, single-arm clinical trials: the ALKA trial, STARTRK-1 trial, and STARTRK-2 trial. Various doses and treatment schedules of Rozlytrek were evaluated in 54 adult patients, of whom 94% received oral Rozlytrek 600 mg once daily. Prior to enrollment, NTRK fusion gene positivity was confirmed by nucleic acid testing at each institution or a central laboratory.
Results (independent review):
- Response rate in 54 adult patients: 57%
- Duration of response:
- ≥6 months: 68% of patients
- ≥12 months: 45% of patients
- Cancer types: Sarcoma, NSCLC, secretory breast analogue carcinoma, breast cancer, thyroid cancer, colorectal cancer, and others
ROS1-Positive Metastatic NSCLC
Efficacy was validated in three clinical trials with various doses and schedules in 51 adult patients. 90% received oral Rozlytrek 600 mg once daily.
- Response rate: 78%
- Duration of response: 55% of patients had responses lasting ≥12 months
Safety Profile
Serious adverse events: congestive heart failure, CNS effects, fractures, hepatotoxicity, hyperuricemia, QT prolongation, and vision impairment.
Common adverse events (≥20%): fatigue, constipation, dysgeusia, edema, dizziness, diarrhea, nausea, paresthesia, dyspnea, myalgia, cognitive impairment, weight gain, cough, vomiting, fever, arthralgia, visual disturbance.
Recommended Dose
For NTRK fusion-positive solid tumors and ROS1-positive metastatic NSCLC: Rozlytrek 600 mg orally once daily.
Tags: #SolidTumors #LungCancer
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4